posted by Helmut Homepage – Vienna, Austria, 2023-06-07 12:22 (177 d 09:06 ago) – Posting: # 23579
Views: 802

Hi Brus,

❝ But nothing is said about the option full-replicate 3-ways, 2-sequences: TRT / RTR,……

Stupid enough. We may run into trouble if we have to assess the study in a partial replicate design for ABE because \(\small{s_\text{wR} < 0.294}\). See this article. At a recent webinar I tried to ask Donald Schuirmann. Was ignored…

❝ … which does seem to be included in the guideline Statistical Approaches to Establishing Bioequivalence.

Pragmatic: This one is the newest one. ;-)

❝ Does this mean that this design can no longer be used?

I don’t see any reason for not doing so. Why should we use an inferior method in lieu of a better one? If in doubt, initiate a controlled correspondence.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,811 posts in 4,783 threads, 1,643 registered users;
30 visitors (0 registered, 30 guests [including 9 identified bots]).
Forum time: 20:29 CET (Europe/Vienna)

Nothing shocks me. I’m a scientist.    Harrison Ford (as Indiana Jones)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz